A first estimate of the percentage of BRAFi-unresponsive patients with BRAF-mutated melanoma came from the BRIM2 phase 2 clinical study [20], in which an impressive unresponsive rate of 47% to vemurafenib monotherapy was observed that was then confirmed by the phase-3 study [14]. Here, BRAF is linked to melanoma.